Advances in RPGR gene therapy for X‑linked retinitis pigmentosa: From preclinical insights to clinical application (Review)
International Journal of Molecular Medicine · 2025
DOI: 10.3892/ijmm.2025.5723 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Medicine, 2025. Verfasst von Yushan Long und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Visual Neuroscience and Stem Cell Engineering, Wuhan University of Science and Technology, Wuhan, Hubei 430065, P.R. China. Hauptthemen laut MEDLINE: Retinitis Pigmentosa, Genetic Therapy, Eye Proteins. Die Arbeit nennt 236 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
X‑linked retinitis pigmentosa, primarily caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene, represents one of the most severe forms of inherited retinal degeneration, with early onset and rapid progression. Conventional interventions, such as vitamin A or docosahexaenoic acid supplementation, offer limited benefits and fail to halt disease progression. By contrast, gene therapy has emerged as a promising approach to alter the disease course. The present review summarizes the clinical phenotypes and pathogenic mechanisms associated with RPGR mutations, focusing on their disruption of ciliary transport and metabolic homeostasis. The present review further discusses advances in preclinical models, including mice, dogs, zebrafish and induced pluripotent stem cell‑derived organoids, that have facilitated the development of RPGR‑targeted therapies. Adeno‑associated virus‑based gene replacement has shown efficacy in restoring retinal structure and function, and several approaches have progressed to early‑phase clinical trials. Despite encouraging outcomes, challenges such as RPGR coding sequence instability, vector delivery efficiency and long‑term safety remain. The present review integrates current mechanistic understanding and therapeutic progress, providing a translational perspective for precision treatment of RPGR‑associated retinal diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Visual Neuroscience and Stem Cell Engineering, Wuhan University of Science and Technology, Wuhan, Hubei 430065, P.R. China.
Zitieren
APA
Long, Y., Qi, J., Zhang, W., Qin, H., & Yao, K. (2025). Advances in RPGR gene therapy for X‑linked retinitis pigmentosa: From preclinical insights to clinical application (Review). International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2025.5723
Vancouver
Long Y, Qi J, Zhang W, Qin H, Yao K. Advances in RPGR gene therapy for X‑linked retinitis pigmentosa: From preclinical insights to clinical application (Review). International Journal of Molecular Medicine. 2025. doi:10.3892/ijmm.2025.5723
BibTeX
@article{Long2025,
author = {Long, Yushan and Qi, Jia and Zhang, Wenliang and Qin, Huan and Yao, Kai},
title = {Advances in RPGR gene therapy for X‑linked retinitis pigmentosa: From preclinical insights to clinical application (Review)},
journal = {International Journal of Molecular Medicine},
year = {2025},
doi = {10.3892/ijmm.2025.5723}
}
EUVIMED